Answers are grounded in this paper and cite their sources.
Classical Hodgkin lymphoma (cHL) accounts for 30% of all lymphomas [1]. Currently, 20–25% of cHL cases relapse or are refractory after first-line standard treatments, leading to the need to better ...
No takes yet. Share an insight, caveat, or question.
Bessi et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: